Skip to main content
Innovotech Inc. logo

Innovotech Inc. — Investor Relations & Filings

Ticker · IOT ISIN · CA45772U1049 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 165 across all filing types
Latest filing 2022-05-24 Regulatory Filings
Country CA Canada
Listing TSXV IOT

About Innovotech Inc.

https://innovotech.ca/

Innovotech Inc. is a specialist in antimicrobial and biofilm solutions, recognized as a pioneer in biofilm product development and contract research. The company focuses on providing innovative and practical solutions to medical, agricultural, and industrial problems caused by microbial biofilms. Key offerings include specialized assay kits used globally for growing microbial biofilms in research applications. Through Innovotech Labs, the company provides comprehensive, accredited (GMP and ISO) contract testing services, including analytical, microbiological, and antimicrobial testing. These services target the pharmaceutical, biotechnology, medical device, and nutraceutical industries, aiming to ensure regulatory compliance and product optimization.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2022-05-24 English
Interim MD&A - English.pdf
Regulatory Filings Classification · 95% confidence The document is a certificate signed by a qualified person, Michelle Liew, P.Eng., certifying compliance with NI 43-101 standards for a technical report related to a mineral project. It is a certification letter confirming the qualifications and independence of the author regarding the technical report. The document does not contain financial data, company performance, or any typical financial or corporate reporting content. It is primarily an officer certification related to a technical report, which fits the criteria for Regulatory Filings (RNS) under the Certification Rule.
2022-05-24 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm (Torys LLP) addressed to multiple Canadian securities commissions. It references a Pricing Supplement dated April 26, 2022, related to Bank of Montreal's AutoCallable Principal At Risk Notes. The letter provides consent to the use of the law firm's opinions in the Pricing Supplement and confirms no misrepresentations in the information derived from their opinions. This is a legal consent letter related to a financing document, not a financial report or earnings release. It is not a full report but a legal attestation related to a capital market instrument. Therefore, it fits best under Regulatory Filings (RNS) as a legal/regulatory compliance document rather than a Capital/Financing Update (CAP) or Audit Report (AR). The document length is short and does not contain financial data or report content itself, so it is not a report publication announcement either.
2022-04-27 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings
2022-04-27 English
Annual MD&A - English.pdf
Regulatory Filings
2022-04-27 English
Audited annual financial statements – English.pdf
Regulatory Filings
2022-04-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.